Strides Pharma Science Limited June quarter results; Pivot Path stake cut to 19.95%
Strides Pharma Science · Pharmaceuticals & Biotechnology
Key highlights
- Board approved on March 19, 2025 the demerger of Arco Lab's Life Sciences and Digital Innovation business into Pivot Path; scheme made effective June 1, 2026.
- Stake in Pivot Path cut to 19.95% on June 30, 2026 for Rs. 1,000 million; net gain Rs. 764.01 million standalone, Rs. 42.07 million consolidated.
- Proposed final dividend of Rs. 5 per equity share, cash outflow Rs. 461 million (approx), subject to shareholder approval at the AGM.
Why it's rated major development: the year-on-year change is 57% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Outcome Of Board Meeting Of The Company Held On July 31, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Strides Pharma Science
- Acquisition / mergerNotableStrides Pharma announces NCLT approval for demerger of Arco Lab's business
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.